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Abstract
A genome-wide screen was conducted for type 2 diabetes progression genes using measures of
elevated fasting glucose levels as quantitative traits from the offspring enrolled in the Framingham
Heart Study. We analyzed young (20–34 years) and old (≥ 35 years) subjects separately, using
single-point and multipoint sibpair analysis, because of the possible differential impact of
progression on the groups of interest. We observed significant linkage with change in fasting
glucose levels on 1q25-32 (p = 5.21 × 10-8), 3p26.3-21.31 (p = 1 × 10-11), 8q23.1-24.13 (p = 2.94 ×
10-6), 9p24.1-21.3 (p = 7 × 10-7), and 18p11.31-q22.1 (p < 10-11). The evidence for linkage on
chromosomes 8 and 18 was consistent for the subset of study participants aged 43 through 55
years.
Background
Type 2 diabetes mellitus is a common metabolic disorder
affecting 4% of the world's adult population, and is
defined by elevated blood glucose levels. The genetic basis
of diabetes is more complex, involving both multiple
interacting genes and environmental factors, which deter-
mine whether diabetes will develop and at what age [1,2].
The pathogenesis of type 2 diabetes requires defects in
both β-cell function and insulin sensitivity. These abnor-
malities result in increased rates of glucose release as well
as decreased glucose clearance from the circulation. Those
who are at high risk of developing type 2 diabetes have
diminished β-cell function at a time when many of them
still have normal glucose tolerance [3,4]. Despite a genetic
predisposition, diabetes may never manifest itself. Hyper-
glycemia, when it occurs, usually does so later in life (>50
years). Most linkage studies have examined fasting glu-
cose levels as a quantitative trait or a dichotomized diabe-
tes phenotype using cross-sectional data, and few
longitudinal studies of diabetes progression exist.
We conducted a genome-wide scan of the rate of change
in fasting glucose levels, as a surrogate for diabetes pro-
gression, using the data from offspring enrolled in the
Framingham Heart Study to address two questions. First,
we asked if the linkage signals identified by examining the
average fasting glucose level during the 20-year interval or
the rate of change in fasting glucose levels were the same.
The hypothesis that drives this inquiry is that genes con-
trolling average fasting glucose levels may be independent
of those controlling the rate of change in fasting glucose.
The second question is a corollary to the first, and relates
to which cross-sectional measures should be used to
derive the rate of change in fasting glucose. In this cohort,
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fasting glucose measurements were taken at five time
points, 8.10, 4.32, 3.51, and 3.75 years apart, respectively.
Thus, four rates (R1-R4) of change in fasting glucose can
be calculated. If the rate and direction of change in fasting
glucose is approximately equal in R1-R4, then use of a sin-
gle measure or some function thereof will suffice. In con-
trast, if the rate and direction of change are sufficiently
different, thereby influencing the sib-sib correlations for
these measures, each rate, R1-R4, independently warrants
closer examination.
We divided our participants into three groups, G1 (<20
years), G2 (20–34 years), and G3 (≥ 35 years) to contrast
rates in groups of comparable age. The rationale behind
this approach is that any locus that affects progression
may act differently in different age groups, since age-at-
onset is also one of the main features used to characterize
type 1 diabetes, type 2 diabetes, and mature onset diabe-
tes of the young. We anticipate that the regions we identi-
fied may harbor genes for progression to type 2 diabetes
or to the prediabetic intermediate state.
Methods
Subjects from the Framingham Heart Study (N = 1023
from the offspring cohort) provided in Problem 1 of the
Genetic Analysis Workshop 13 were divided into three
groups based on the age at baseline (<20 years (G1; N =
78), between 20–34 years (G2; N = 525), and ≥ 35 years
(G3; N = 420)), after excluding individuals with incom-
plete data.
We initially conducted exploratory data analysis to deter-
mine the stage of diabetes in the subjects. We examined
the number of individuals who had overt diabetes,
defined as fasting glucose levels ≥ 126 mg/dl occurring at
least twice in the ~20 year interval. Potential diabetes,
defined as fasting glucose levels ≥ 126 mg/dl occurring at
least once in the ~20 year interval, was also ascertained. To
determine the age-specific stages of diabetes, we plotted
changes in levels of mean fasting glucose stratified by age
at baseline. We also examined the average fasting glucose
levels at baseline and each following time point by subdi-
viding the population into those with potential diabetes
(≥ 26 mg/dl), those between 100–125 mg/dl, and normo-
glycemic individuals (<100 mg/dl). The rationale for this
trifurcation was that those with clinical diabetes or
impaired glucose tolerance might have undergone thera-
peutic interventions.
Fasting glucose levels were log-transformed prior to anal-
ysis to reduce skewness and to approximate normality. We
used multiple linear regression models to examine the
effects of sex, systolic blood pressure, and triglycerides,
along with first order interactions of these effects, on fast-
ing glucose levels at each time point. The progression rates
were determined for each individual by calculating the
difference in the residuals of fasting glucose levels
between two observed time points. Four progression rates,
estimated as differences in the standardized residuals
divided by the age differences between time points 1 and
2 (R1), 2 and 3 (R2), 3 and 4 (R3), and 4 and 5 (R4), were
estimated. Four newly derived phenotypes (R1-R4), and
the mean of standardized residuals at five time points (20-
year mean), were adjusted by a constant (× 100) and were
analyzed as quantitative traits in all further analyses.
Sibling correlations for five derived phenotypes were esti-
mated with the FCOR program in S.A.G.E. [5]. Sharing
probabilities for identity by descent (IBD) were estimated
at each marker and were interpolated at 2cM intervals
using the GENIBD program [5]. We performed both sin-
gle-point and multipoint linkage analyses on five quanti-
tative traits (R1-R4, 20-year mean) in each stratum (G1-
G3) using SIBPAL [5]. The weighted combination of
squared trait difference and squared mean-corrected trait
sum was used as the dependent variable in a Haseman-
Elston regression model [6-8]. We selected the linkage evi-
dence based on the genome-wide thresholds for mapping
loci underlying complex traits [9]; the P-value for signifi-
cant linkage is 2.2 × 10-5 and the P-value for suggestive
linkage is 7.4 × 10-4.
Results
Longitudinal data analysis
Fasting glucose measurements for R1 were 8.10 years
apart on average. Similarly, R2, R3, and R4 were based on
measurements 4.32, 3.51, and 3.75 years apart, respec-
tively. Average time between the first and fifth glucose
measure was 19.68 years (Figure 1a). Unexpectedly, the
average glucose levels declined with subjects' age from
time point 1 to time point 3, and then increased again at
the later ages. The trends were consistent in all age groups
(Figure 1a).
We observed that a small subset of individuals (N = 12)
with potentially overt diabetes remained diabetic at all
time points (Figure 1b), although a small decline in mean
fasting glucose was observed from time point 3 through 5.
The fasting glucose levels in the <126 mg/dl groups, which
constituted the majority of the sample, demonstrated a
decrease in time points 2 and 3. We also estimated how
many patients had type 2 diabetes. Within the G2 sub-
group, only 8 subjects had overt diabetes, while another
18 had potential diabetes. Similarly, within the G3 sub-
group, 56 and 32 individuals had overt and potential dia-
betes, respectively. The G1 subgroup had no subjects with
overt diabetes or potential diabetes.BMC Genetics 2003, 4 http://www.biomedcentral.com/1471-2156/4/s1/S8
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Linkage analysis
There were 19, 259, and 293 informative sibpairs for G1,
G2, and G3, respectively (Table 1). The mean size of sib-
ships for G1, G2, and G3 is 1.28, 2.35, and 2.26, respec-
tively (Table 1). The mean size of sibships between G2
and G3 was significantly different (p  < 0.05); G2 had
smaller sibships (Table 1). Due to the small sample size
G1 was not included in further analysis (Table 1), nor
were sibpairs whose members were split between two of
these groups (e.g., G2 and G3). We observed that sex had
a significant effect on fasting glucose levels and utilized
sex-adjusted residuals for calculation of rates.
We examined correlations between siblings for mean fast-
ing glucose and R1-R4 in G2 and G3 (Table 2). In general,
we observed positive correlations for R3, R4, and 20-year
mean glucose in G2, and for R1 and 20-year mean glucose
Exploratory analysis of change in fasting glucose Figure 1
Exploratory analysis of change in fasting glucose a. Change in levels of mean fasting glucose when stratified by 
age at baseline. At baseline, the mean ages of grouped subjects were approximately 16 years for G1, 27 years for G2, and 43 
years for G3, respectively. The mean of the fasting glucose levels over the five time points was 91.33 mg/dl in G1, 93.82 mg/dl 
in G2, and 102.06 mg/dl in G3, respectively. b. Change in mean fasting glucose levels stratified by initial levels.Fasting 
glucose levels were grouped at baseline as <100 mg/dl, 100–125 mg/dl, ≥ 126 mg/dl, and followed over all five time points.BMC Genetics 2003, 4 http://www.biomedcentral.com/1471-2156/4/s1/S8
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in G3. Sibling correlations fluctuated from positive to
negative to positive from R1-R4 in the G3 group. The
correlations also fluctuated in G2, but not as significantly
(Table 2).
We focused on the linkage results from R4 in G2 subjects
(age range: 43–47 years) who were approximately compa-
rable in age to individuals in the R1 and R2 of G3 (age
range: 43–56 years). Our analysis demonstrated evidence
for linkage with R4 (G2), and R1 and R2 (G3), on chro-
mosomes 8 and 18 (Table 3). We also observed significant
evidence for linkage with R4 (G2) on chromosome 1, 3,
and 9, and suggestive linkage on chromosomes 11 (Table
3). The linkage on chromosome 8 was consistent from
ages 43 through 55 years (Figure 2). Suggestive linkage
with 20-year mean glucose in G3 was obtained on chro-
mosome 11 (Table 3).
Discussion
Our analysis demonstrates that change in glucose levels
over time is not linear in this cohort (Figures 1a and 1b).
There are many explanations for the non-linear trend.
Therefore, we focused on age-specific strata. We observed
fluctuations in sibling correlations for G3, possibly
because a greater number of subjects within this group are
in the process of progressing to impaired glucose toler-
ance (IGT) or to type 2 diabetes (56 overt and 32 poten-
tial). However, only 12 of these remained diabetic across
the entire 20-year period. The others cycled between nor-
moglycemia, IGT, and diabetes. This oscillation, coupled
with the overall decrease in the mean fasting glucose, at
time points 2–4 probably lead to the difference in the sib-
sib correlations in R1-R4 for G3. Similar factors may have
affected the G2 sib-sib correlations, but to a lesser degree,
because fewer diabetics were present in this group.
Diurnal variations and fluctuations in fasting glucose lev-
els are part of the natural history of the disease [10,11]. To
identify genes that influence progression, we need to cap-
ture the maximal sib-sib correlation associated with con-
version of sibs from normoglycemia to IGT or from
normoglycemia/IGT to diabetes. When analyzing a quan-
titative trait any increase from one time point to the next
may be informative. Siblings appearing discordant for
progression are some composite of those truly discordant,
and those occasionally discordant due to fluctuations in
glycemic status. These discrepancies will influence R1-R4
as well as the overall rate of change. Thus, estimation of
overall rates of progression as the explanatory variable
will only be useful if averaging the data captures the max-
imal sib-sib correlation described above.
In examining the sib-sib correlations, our conclusion is
that the R3-R4 (G2 and G3) measurements may be our
best approximations for the longitudinal measures. We
recognize that the current data set is limited in this regard,
and does not fully represent type 2 diabetes progression.
To improve estimates of the rate of change in fasting glu-
cose levels, each measurement must be adjusted for cov-
ariates, such as medication use or diet modification,
which were unavailable to us.
If the effect of a progression locus is manifested at specific
ages, then evidence for such loci may be obtained at spe-
cific age epochs with R4 in G2 being equivalent to R1-R2
in G3. We observed evidence for linkage at 18p11 in R4
for G2 and R1 for G3, and 18q21 in R4 for G2, as well as
Table 1: Descriptive statistics for sibships in G2 and G3 groups
Groups Sibships Mean Size (Min, Max) Sibpairs
G1 61 1.28 ± 0.52 (1, 3) 19
G2 146 2.35 ± 0.61 (2, 5) 259
G3 98 2.76 ± 1.07 (2, 7) 293
Table 2: Sib-sib correlations for R1-R4 and mean glucose levels for G2 and G3 subjects
Rate
G r o u p R 1R 2R 3R 4 M e a n  G l u c o s e
G2 0.097 0.041 0.160 0.123 0.121
G3 0.150 -0.058 0.044 0.012 0.268BMC Genetics 2003, 4 http://www.biomedcentral.com/1471-2156/4/s1/S8
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R2 for G3 (Table 3). Previous evidence for linkage on
18p11 has been reported in conjunction with obesity for
type 2 diabetes [12]. The linkage on chromosome 18q is
novel. Similarly, we observed evidence for linkage at
8q23-24 in R4 for G2 and in R1-R2 for G3 (Figure 2).
Interestingly, the 8q23 region was reported as a locus for
type 1 diabetes in a genetically isolated population from
the Netherlands [13]. Two additional regions on chromo-
some 3 (~65 cM) and chromosome 11 (84–91 cM), previ-
ously identified from the Finnish population [14,15], also
showed evidence of linkage (Table 3).
In a previous analysis of the Framingham Heart Study off-
spring cohort using variance components, a region on
chromosome 1q (218 cM from pter; multipoint LOD =
2.33) was linked with the current fasting glucose levels
[16]. We also observed a linkage signal on 1q in R4 (G2).
This period is closest to the current time point described
Comparison of linkage results for young (G2) versus old (G3) subjects Figure 2
Comparison of linkage results for young (G2) versus old (G3) subjects Genetic distance (cM) is plotted for markers 
on chromosome 8 on the x-axis. R1-R4 in G2 was compared with R1-R4 in G3 (left and right; solid lines), and each contrasted 
with the mean glucose (dotted lines). The negative log10 (P-value) for linkage is plotted on the y-axis. P-values of 10-2 and 10-4 
are shown as horizontal dotted lines perpendicular to the y-axis.BMC Genetics 2003, 4 http://www.biomedcentral.com/1471-2156/4/s1/S8
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in the Framingham Heart Study, since it was calculated
using data from the time points 4 and 5. Since this locus
was observed both in the original Framingham data and
in our analysis, it may control both mean glucose levels
and progression.
Conclusions
Our study provides further insights into how quantitative
factors, such as rates of changes in fasting glucose levels,
may play a role in the progression to type 2 diabetes. The
resulting evidence from our analysis, particularly the
linkage on chromosome 8 to the progression rate, and on
chromosome 11 to the 20-year mean glucose, confirmed
this hypothesis, and presents a compelling reason for fur-
ther examination of these regions.
While our results are interesting, we conclude that future
studies of diabetes progression need to refine measures to
give consistent results between time points and groups.
The source of fluctuations in the sib-sib correlations in G2
and G3 needs to be identified. For example, fasting glu-
cose levels could be adjusted for additional covariates,
specifically interventional therapy, as well as other varia-
bles that may enable us to reduce the intra-individual var-
iability and minimize the oscillatory effect.
Acknowledgments
This study was supported in part by DK54644 and DK57292 from the 
National Institute of Diabetes and Digestive and Kidney Diseases, HL07567 
from the National Heart Lung and Blood Institute, and HG01577 from 
National Human Genome Research Institute. The results reported were 
obtained by using the program package S.A.G.E., which is supported by U.S. 
Public Health Service Resource grant RR03655 from the National Center 
for Research Resources.
References
1. Hayden MR: Islet amyloid, metabolic syndrome, and the natu-
ral progressive history of type 2 diabetes mellitus. J Pancreas
2002, 3:126-138.
2. UK Prospective Diabetes Study Group: Intensive blood-glucosec-
ontrol with sulphonylureas or insulin compared with conven-
tional treatment and risk of complications in patients with
type 2 diabetes (UKPDS 33). Lancet 2001, 352:837-853.
3. Bell GI, Polonsky KS: Diabetes mellitus and genetically pro-
grammed defects in β-cell function. Nature 2001, 414:788-787.
4. Kahn SE: The importance of β-cell failure in the development
and progression of type 2 diabetes. J Clin Endrocrinol Metab 2001,
86:4047-4058.
5. Statistical Solutions: S.A.G.E., Statistical Analysis for Genetic
Epidemiology, version 4.2. Cork, Ireland, Statistical Solutions 2002.
6. Haseman JK, Elston RC: The investigation of linkage between a
quantitative trait and a marker locus. Behav Genet 1972, 2:3-19.
7. Elston RC, Buxbaum S, Jacobs KB, Olson JM: Haseman and Elston
revisited. Genet Epidemiol 2000, 19:1-17.
8. Shete S, Jacobs K, Elston RC: Adding further power to the Hase-
man and Elston method for detecting linkage in larger sib-
ships: weighting sums and differences.  Human Hered 2003,
55:79-85.
9. Lander E, Kruglyak L: Genetic dissection of complex traits:
guidelines for interpreting and reporting linkage results. Nat
Genet 1995, 11:241-247.
10. Troisi RJ, Cowie CC, Harris MI: Diurnal variation in fasting
plasma glucose: implications for diagnosis of diabetes in
patients examined in the afternoon. JAMA 2000, 284:3157-3159.
11. Trovati M, Ponziani MC, Massucco P, Anfossi G, Mularoni EM, Burza-
cca S, Tassone F, Perna P, Traversa M, Cavalot F: Blood glucose
pre-prandial baseline decreases from morning to evening in
type 2 diabetes: role of fasting blood glucose and influence on
post-prandial excursions. Eur J Clin Invest 2002, 32:179-186.
12. Parker A, Meyer J, Lewitzky S, Rennich JS, Chan G, Thomas JD, Orho-
Melander M, Lehtovirta M, Forsblom C, Hyrkko A, Carlsson M, Lind-
gren C, Groop LC: A gene conferring susceptibility to type 2
Table 3: Comparison of linkage results for subjects in G2 (R4) versus in G3 (R1 and R2)
Ch # Phenotype 
Group Rate: 
Age




1 R4G2: 43–47 q25 ~ q32 176 ~ 218 GATA48B01 A5.21 × 10-8
R2G3: 51–55 p31.1 ~ p22.1 114 ~ 137 ATA29D04 0.0074
G3 – Mean  p31.1 ~ p22.1 114 ~ 140 ATA2E04 0.0074
3 R4G2: 43–47 p26.3 ~ p21.31 6 ~ 71 GATA164B08 1 × 10-11
G3 – Mean  p14.1 ~ q12.3 91 ~ 119 GATA128C02 0.0049
8 R4G2: 43–47 q23.1 ~ q24.13 119 ~ 135 GATA7G07 2.94 × 10-6
R1G3: 43–51 q24.13 ~ q24.22 135 ~ 148 GATA21C12 0.0025
R2G3: 51–55 q24.13 ~ q24.22 135 ~ 148 GATA21C12 B1.06 × 10-4
9 R4G2: 43–47 p24.1 ~ p21.3 14 ~ 44 GATA27A11 7.0 × 10-7
11 R4G2: 43–47 p15.5 ~ p15.2 2 ~ 21 GATA23F06 9.9 × 10-4
q22.3 ~ q24.3 101 ~ 131 GATA23E06 3.14 × 10-4
G2 – Mean  q12.1 ~ q13.5 56 ~ 76 GATA90D07 0.0090
G3 – Mean 
Glucose
p14.1 ~ q12.3 91 ~ 119 GATA30G01 6.6 × 10-4
18 R4G2: 43–47 p11.31 ~ q22.1 13 ~ 107 GATA26C03 < 10-11
R1G3: 43–51 p11.31 3 ~ 7 321xc9 0.007
R2G3: 51–55 q21.2 ~ q21.32 80 ~ 89 ATA7D07 0.0059
ABold p-values indicate statistically significant evidence for linkage. BItalicized p-values are suggestive evidence for linkage by conventional criteria 
[9]; marker range in the table corresponds to p-values < 0.01.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Genetics 2003, 4 http://www.biomedcentral.com/1471-2156/4/s1/S8
Page 7 of 7
(page number not for citation purposes)
diabetes in conjunction with obesity is located on chromo-
some 18p11. Diabetes 2001, 50:675-680.
13. Vaessen N, Heutink P, Houwing-Duistermaat JJ, Snijders PJLM, Rade-
maker T, Testers L, Batstra MR, Sandkuijl LA, van Duijn CM, Oostra
BA: A genome-wide search for linkage-disequilibrium with
type 1 diabetes in a recent genetically isolated population
from the Netherlands. Diabetes 2002, 51:856-859.
14. Lindgren CM, Mahtani MM, Widen E, McCarthy MI, Daly MJ, Kirby A,
Reeve MP, Kruglyak L, Parker A, Meyer J, Almgen P, Lehto M, Kan-
ninen T, Tuomi T, Groop LC, Lander ES: Genomewide search for
type 2 diabetes mellitus susceptibility loci in Finnish families:
The Botnia Study. Am J Hum Genet 2002, 70:509-516.
15. Ghosh S, Watanbe RM, Valle TT, Hauser ER, Magnuson VL, Langefeld
CD, Ally DS, Mohlke KL, Silander K, Kohtamaki K, Chines P, Balow J
Jr, Birznieks G, Chang J, Eldridge W, Erdos MR, Karanjawala ZE,
Knapp JI, Kudelko K, Martin C, Morales-Mena A, Musick A, Musick T,
Pfahl C, Porter R, Rayman JB: The Finland-United States investi-
gation of non-insulin-dependent diabetes mellitus genetics
(FUSION) study. I. An autosomal genome scan for genes
that predispose to type 2 diabetes.  Am J Hum Genet 2000,
67:1174-1185.
16. Meigs JB, Panhuysen CIM, Myers RH, Wilson PWF, Cupples LA: A
genome-wide scan for loci linked to plasma levels of glucose
and HbA1c in a community-based sample of Caucasian
pedigrees. Diabetes 2002, 51:833-884.